[go: up one dir, main page]

MX2019002925A - Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer. - Google Patents

Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.

Info

Publication number
MX2019002925A
MX2019002925A MX2019002925A MX2019002925A MX2019002925A MX 2019002925 A MX2019002925 A MX 2019002925A MX 2019002925 A MX2019002925 A MX 2019002925A MX 2019002925 A MX2019002925 A MX 2019002925A MX 2019002925 A MX2019002925 A MX 2019002925A
Authority
MX
Mexico
Prior art keywords
cancer treatment
immune modulation
tlr9 agonists
tlr9
agonists
Prior art date
Application number
MX2019002925A
Other languages
English (en)
Inventor
Wang Daqing
Jiang Wayne
Agrawal Sudhir
Original Assignee
Idera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idera Pharmaceuticals Inc filed Critical Idera Pharmaceuticals Inc
Publication of MX2019002925A publication Critical patent/MX2019002925A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a métodos para tratar un tumor, incluyendo un tumor metastásico, con un agonista de TLR9 en combinación con una terapia con inhibidores del punto de control inmune.
MX2019002925A 2016-09-15 2017-09-15 Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer. MX2019002925A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394845P 2016-09-15 2016-09-15
US201762486738P 2017-04-18 2017-04-18
PCT/US2017/051742 WO2018053242A1 (en) 2016-09-15 2017-09-15 Immune modulation with tlr9 agonists for cancer treatment

Publications (1)

Publication Number Publication Date
MX2019002925A true MX2019002925A (es) 2019-09-05

Family

ID=61620152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002925A MX2019002925A (es) 2016-09-15 2017-09-15 Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.

Country Status (10)

Country Link
US (6) US10463686B2 (es)
EP (1) EP3512499A4 (es)
JP (2) JP7200093B2 (es)
KR (1) KR20190096936A (es)
CN (1) CN110114057A (es)
AU (1) AU2017325981A1 (es)
CA (1) CA3036978A1 (es)
IL (2) IL292658A (es)
MX (1) MX2019002925A (es)
WO (1) WO2018053242A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US10463686B2 (en) 2016-09-15 2019-11-05 Idera Pharmaceuticals, Inc. Immune modulation with TLR9 agonists for cancer treatment
BR112019007369A2 (pt) 2016-10-11 2019-07-16 Agenus Inc anticorpos anti-lag-3 e métodos de uso dos mesmos
EP4275698A3 (en) 2017-05-01 2024-05-15 Agenus Inc. Anti-tigit antibodies and methods of use thereof
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
KR102522693B1 (ko) 2017-05-19 2023-04-17 우시 바이올로직스 (상하이) 컴퍼니 리미티드 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
CN113226366A (zh) * 2018-10-18 2021-08-06 艾德拉药物股份有限公司 用于治疗癌症的tlr9调节剂
CA3113895A1 (en) * 2018-11-01 2020-05-07 Faron Pharmaceuticals Oy Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages
CN113490687A (zh) 2018-12-26 2021-10-08 西利欧发展公司 抗ctla4抗体和其使用方法
MX2022011155A (es) * 2020-03-09 2023-01-04 Dynavax Tech Corp Inmunización activa de refuerzo contra tétanos, difteria y tosferina.
US20230374523A1 (en) * 2020-09-22 2023-11-23 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists
TW202304965A (zh) 2021-05-04 2023-02-01 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1200580E (pt) 1999-08-13 2005-03-31 Hybridon Inc Modulacao da estimulacao imunitaria mediada por oligonucleotidos cpg atraves de modificacao posicional de nucleosidos
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
KR100881923B1 (ko) 2000-12-27 2009-02-04 다이나박스 테크놀로지 코퍼레이션 면역자극 폴리뉴클레오티드 및 그것의 사용 방법
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
WO2004058179A2 (en) * 2002-12-23 2004-07-15 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
KR101137572B1 (ko) 2003-06-11 2012-05-30 이데라 파마슈티칼즈, 인코포레이티드 안정화된 면역조절 올리고뉴클레오티드
EP1648913A4 (en) 2003-07-15 2008-09-10 Idera Pharmaceuticals Inc SYNERGISTIC STIMULATION OF THE IMMUNE SYSTEM WITH IMMUNOSTIMULATING OLIGONUCLEOTIDES AND / OR IMMUNOMER COMPOUNDS RELATED TO CYTOKINES AND / OR CHEMOTHERAPEAN MEDICAMENTS OR RADIATION THERAPY
CN100482673C (zh) 2003-07-15 2009-04-29 艾德拉药物股份有限公司 使用免疫刺激性寡核苷酸和/或免疫子化合物结合细胞因子和/或化疗剂或放射治疗对免疫系统的协同刺激作用
HUE036894T2 (hu) 2004-06-15 2018-08-28 Idera Pharmaceuticals Inc Immunstimuláló oligonukleotid multimerek
US7427405B2 (en) 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
BRPI0612408A2 (pt) 2005-07-07 2010-11-03 Pfizer terapia para tratamento de cáncer em combinação com anticorpo anti-ctla-4 e oligodesoxinucleotìdeo sintético contendo o motivo cpg
AU2006310339B2 (en) 2005-11-04 2013-01-10 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
CN101379195B (zh) 2005-12-20 2012-05-09 艾德拉药物股份有限公司 含有不同长度回文片段的回文免疫调节性寡核苷酸(imotm)的免疫刺激活性
US20080031887A1 (en) 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
CN101610671A (zh) 2006-12-12 2009-12-23 艾德拉药物股份有限公司 合成的tlr9激动剂
ES2585239T3 (es) 2007-08-01 2016-10-04 Idera Pharmaceuticals, Inc. Nuevos agonistas sintéticos de TLR9
KR20110111517A (ko) 2009-01-30 2011-10-11 이데라 파마슈티칼즈, 인코포레이티드 Ｔｌｒ9의 합성 효능제
US20130142815A1 (en) 2010-02-09 2013-06-06 Georiga Health Sciences Univ. Research Inst., Inc. Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase
WO2011143656A2 (en) 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
FR2975600B1 (fr) * 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
EP2758080B1 (en) * 2011-09-19 2018-03-07 The Johns Hopkins University Cancer immunotherapy
WO2014047085A2 (en) 2012-09-20 2014-03-27 Rongfu Wang Prostate-specific tumor antigen and uses thereof
WO2015061752A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
EP4029508A1 (en) 2014-10-10 2022-07-20 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonists and checkpoint inhibitors
WO2016128542A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
ES2752063T3 (es) 2015-05-29 2020-04-02 Dynavax Tech Corp Administración intrapulmonar de agonistas polinucleotídicos del receptor de tipo toll 9 para el tratamiento del cáncer de pulmón
ES2985394T3 (es) 2015-05-29 2024-11-05 Merck Sharp & Dohme Llc Combinación de un antagonista de PD-1 y un oligonucleótido de tipo CpG-C para el tratamiento del cáncer
US10463686B2 (en) 2016-09-15 2019-11-05 Idera Pharmaceuticals, Inc. Immune modulation with TLR9 agonists for cancer treatment

Also Published As

Publication number Publication date
JP2019529415A (ja) 2019-10-17
IL265370B (en) 2022-06-01
US20200138848A1 (en) 2020-05-07
WO2018053242A1 (en) 2018-03-22
JP2022009200A (ja) 2022-01-14
US11224611B2 (en) 2022-01-18
CN110114057A (zh) 2019-08-09
US10772907B2 (en) 2020-09-15
IL265370A (en) 2019-05-30
US10463686B2 (en) 2019-11-05
EP3512499A4 (en) 2020-08-05
US20220088054A1 (en) 2022-03-24
US20180125877A1 (en) 2018-05-10
US10835550B2 (en) 2020-11-17
AU2017325981A1 (en) 2019-04-11
IL292658A (en) 2022-07-01
KR20190096936A (ko) 2019-08-20
JP7200093B2 (ja) 2023-01-06
EP3512499A1 (en) 2019-07-24
US20210052625A1 (en) 2021-02-25
US20210038630A1 (en) 2021-02-11
CA3036978A1 (en) 2018-03-22
US20200054663A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
MX2019002925A (es) Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
ZA201802966B (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JO3553B1 (ar) تعديل المناعة ضد الورم
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
MX2022008868A (es) Tratamiento del cancer con tg02.
PH12017550063A1 (en) Combination therapies for treating cancers
MX2016002273A (es) Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MA39817A (fr) Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
MX2020003770A (es) Terapias de combinacion para tratar cancer.
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
EA201991818A1 (ru) Лечение рака
EA201890868A1 (ru) Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
NZ754522A (en) Oxabicycloheptanes for modulation of immune response
TW201613587A (en) Medical treatments based on anamorelin
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
EA202190600A1 (ru) Комбинированная терапия для лечения рака предстательной железы
EA201990411A1 (ru) Способы лечения рака предстательной железы